Nebula Research & Development LLC Purchases 7,871 Shares of Cabot Co. (NYSE:CBT)

Nebula Research & Development LLC raised its position in Cabot Co. (NYSE:CBT) by 85.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,134 shares of the specialty chemicals company’s stock after acquiring an additional 7,871 shares during the period. Nebula Research & Development LLC’s holdings in Cabot were worth $1,565,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Barclays PLC lifted its position in Cabot by 103.9% in the third quarter. Barclays PLC now owns 113,614 shares of the specialty chemicals company’s stock worth $12,699,000 after purchasing an additional 57,907 shares during the period. World Investment Advisors LLC acquired a new position in shares of Cabot in the 3rd quarter valued at $3,161,000. Wilmington Savings Fund Society FSB bought a new position in shares of Cabot during the 3rd quarter worth about $1,651,000. Tidal Investments LLC boosted its position in shares of Cabot by 2.9% during the 3rd quarter. Tidal Investments LLC now owns 11,917 shares of the specialty chemicals company’s stock valued at $1,332,000 after acquiring an additional 340 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in shares of Cabot during the 3rd quarter valued at about $654,000. Institutional investors own 93.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on CBT. UBS Group cut their price target on shares of Cabot from $93.00 to $83.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. JPMorgan Chase & Co. dropped their target price on Cabot from $105.00 to $85.00 and set an “underweight” rating for the company in a report on Friday, February 21st. Mizuho decreased their price target on Cabot from $122.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, StockNews.com upgraded Cabot from a “hold” rating to a “buy” rating in a research note on Thursday, April 17th.

Cabot Stock Performance

NYSE CBT opened at $79.27 on Friday. Cabot Co. has a 1-year low of $73.63 and a 1-year high of $117.46. The company has a 50 day moving average of $81.93 and a 200-day moving average of $93.81. The company has a current ratio of 2.00, a quick ratio of 1.29 and a debt-to-equity ratio of 0.72. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of 10.53, a PEG ratio of 0.74 and a beta of 1.04.

Cabot (NYSE:CBT) last released its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. On average, equities analysts forecast that Cabot Co. will post 7.57 earnings per share for the current fiscal year.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.